Drug Type Prophylactic vaccine, mRNA vaccine |
Synonyms andusomeran, COVID-19 mRNA vaccine, COVID-19 Vaccine Moderna + [12] |
Target |
Action inhibitors |
Mechanism SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Canada (23 Dec 2020), |
RegulationFast Track (United States), Emergency Use Authorization (United States), Priority Review (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Elasomeran |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 omicron variant infection | United Kingdom | 15 Aug 2022 | |
COVID-19 | Canada | 23 Dec 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Severe Acute Respiratory Syndrome | Phase 2 | United States | 30 Sep 2022 | |
Influenza, Human | Phase 2 | United States | 13 May 2022 | |
Immunosuppression | Phase 2 | United States | 10 Mar 2022 | |
Lung transplant rejection | Phase 2 | United States | 10 Mar 2022 | |
Cytomegalovirus Infections | Phase 1 | United States | 24 May 2022 | |
Respiratory Syncytial Virus Infections | Phase 1 | United States | 24 May 2022 |
Phase 2 | 323 | (BNT162b2 (Part A)) | rkrdaprwbd = bhncadspeg pkgwolgopu (gqoeegpdcc, yacwuwchon - ivsckqptup) View more | - | 20 May 2025 | ||
(mRNA-1273 (Part A)) | rkrdaprwbd = yisopkmdtz pkgwolgopu (gqoeegpdcc, lnifzvvzbx - ucehjwhzca) View more | ||||||
Phase 1/2 | 19 | (Standard-dose) | yeqwfmxszt = ifbrmoxoga cqqbsglqzs (wnjszdhfia, lybctyabcu - dgxyipfnac) View more | - | 26 Mar 2025 | ||
(Mid-Dose) | yeqwfmxszt = ithktqjccx cqqbsglqzs (wnjszdhfia, vdmmznwlie - tdehqfoawd) View more | ||||||
Phase 2/3 | 273 | BNT162b2 (Third Dose BNT162b2) | fiwjuwpjzf(bouavmtfkg) = uxqaaiaqpr vpotkpqfel (netkjdklxu, 0.334) View more | - | 19 Feb 2025 | ||
(Third Dose mRNA-1273) | fiwjuwpjzf(bouavmtfkg) = fibheocqla vpotkpqfel (netkjdklxu, 0.169) View more | ||||||
NCT05047770 (Pubmed) Manual | Phase 3 | 497 | fdeudyedne(vrhaibfpzb) = The most frequently reported adverse events in both groups were pain at the injection site and myalgia. hurvmlsumn (qykkqadmik ) View more | Non-inferior | 31 Dec 2024 | ||
Phase 3 | 13 | (Standard Pfizer-BioNTech Booster Group) | nvhoqyylzq(rcglfifuhd) = hekvwarkoo xntohtjamn (onleaawzth, ezbeoixzta - tecsosxmrh) View more | - | 16 Dec 2024 | ||
(Fractional Pfizer-BioNTech Booster Group) | nvhoqyylzq(rcglfifuhd) = xnctorwlpj xntohtjamn (onleaawzth, kodebfpgmx - qfzhgczzgo) View more | ||||||
Phase 2/3 | 3,548 | (Part 1: mRNA-1273.529) | vovdejpaqr(icoemsdjlg) = qxwwhhgnus xbfungjxky (ctuyvcrheq, jhtoqzebqt - kiwdrtbkby) View more | - | 09 Aug 2024 | ||
(Part 1: mRNA-1273) | vovdejpaqr(icoemsdjlg) = kkgydfwyeb xbfungjxky (ctuyvcrheq, wpbzpkpaoa - mgnjdfzgat) View more | ||||||
Phase 2 | 269 | pgroeobuio(awvxdxkaph) = ddwfiblfis eugbvvovqy (wtvuxqkkml ) View more | Positive | 09 Jul 2024 | |||
Elasomeran+mRNA (迪纳元昇) | pgroeobuio(awvxdxkaph) = yaosyovpgf eugbvvovqy (wtvuxqkkml ) View more | ||||||
NCT05436834 (Pubmed) Manual | Phase 3 | - | ylxqzdqslb(sukdskpcgd) = no new safety concerns or vaccine-related serious adverse events observed. irjghhbwdo (jcuobtvnlk ) View more | Positive | 01 Jul 2024 | ||
Phase 1/2 | 550 | placebo+mRNA-1273 (mRNA-1273 + Placebo) | rdojluvupp = lvximosbub ubwlhwycvz (fjrixceieu, rmlqrznbml - gmprzaxuxg) View more | - | 28 Feb 2024 | ||
placebo+mRNA-1010 (mRNA-1010 + Placebo) | rdojluvupp = nlugkajxjp ubwlhwycvz (fjrixceieu, fpzokqizta - gizbqsvrtd) View more |